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This study investigated how maternal overnutrition and
obesity regulate expression and activation of proteins
that facilitate lipid transport in the placenta. To create
a maternal overnutrition and obesity model, primiparous
C57BL/6 mice were fed a high-fat (HF) diet throughout
gestation. Fetuses from HF-fed dams had significantly
increased serum levels of free fatty acid and body fat.
Despite no significant difference in placental weight,
lipoprotein lipase (LPL) protein levels and activity were
remarkably elevated in placentas from HF-fed dams.
Increased triglyceride content and mRNA levels of
CD36, VLDLr, FABP3, FABPpm, and GPAT2 and -3 were
also found in placentas from HF-fed dams. Although
both peroxisome proliferator–activated receptor-g
(PPARg) and CCAAT/enhancer binding protein-a protein
levels were significantly increased in placentas of the
HF group, only PPARg exhibited a stimulative effect on
LPL expression in cultured JEG-3 human trophoblasts.
Maternal HF feeding remarkably decreased SIRT1 ex-
pression in placentas. Through use of an SIRT1 activator
and inhibitor and cultured trophoblasts, an inhibitory ef-
fect of SIRT1 on LPL expression was demonstrated. We
also found that SIRT1 suppresses PPARg expression in
trophoblasts. Most importantly, inhibition of PPARg
abolished the SIRT1-mediated regulatory effect on LPL
expression. Together, these results indicate that mater-
nal overnutrition induces LPL expression in trophoblasts
by reducing the inhibitory effect of SIRT1 on PPARg.
Obesity is a risk factor of type 2 diabetes and car-
diovascular diseases. Studies have demonstrated that
prepregnant maternal BMI and gestational weight gain
are closely associated with birth weight (1–3). Impor-
tantly, high birth weight predicts higher BMI and obesity
during both childhood and adulthood (4,5). Therefore, in
addition to calorie-rich foods, sedentary lifestyle, and
genetic defects, undesirable intrauterine metabolic expo-
sure might contribute significantly to the ongoing obesity
epidemic.
At birth, infant body weight is mainly determined by
lean and fat tissue mass. Human studies have demon-
strated that maternal obesity and excess gestational
weight gain increase infant body fat and birth weight
(1,3,6). Although rodent neonates have very limited
amounts of fat tissue mass compared with humans,
maternal high-fat (HF) feeding increases fat in both
fetuses and newborn mice (7,8). Fetal lipid deposition
increases exponentially with gestational age (9,10).
Some of the accumulated lipids arise from de novo li-
pogenesis, but the bulk of fetal lipids is derived from
the maternal circulation through placental fatty acid
(FA) transport (10).
Triglyceride (TG)-enriched VLDL in maternal circula-
tion is the main FA supplier for the fetus (9,10). TGs
cannot be transported through the placenta. Only non-
esterified FAs can be taken up by the microvillus mem-
brane and transported to the fetus. Therefore, FAs from
TGs should be released by lipases at the placenta. Several
TG lipases, including lipoprotein lipase (LPL) and endo-
thelial lipase, have been identified in human and rodent
placentas (10–12).
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LPL gene expression increases dramatically during the
last trimester of pregnancy, paralleling increased placental
FA transport (12–14). Placental LPL expression and activ-
ity positively correlate with fetal size and fetal adipose
tissue mass (14). Importantly, studies have demonstrated
that maternal obesity or HF feeding increases placental
LPL expression and activity (15,16). Therefore, increased
placental LPL may enhance fetal FA supply and increase
fetal fat accretion. However, the mechanisms of maternal
overnutrition and/or obesity-increased placental LPL ex-
pression are largely unknown.
SIRT1 (silent mating type information regulation 2
homology 1) is an NAD-dependent protein deacetylase
that regulates energy metabolism, aging, and other
cellular processes (17). Energy deficiency increases the
NAD level and NAD/NADH ratio, leading to SIRT1 activa-
tion (18). In contrast, sufficient nutrient supply provides
substrates to generate ATP, whereas NAD is converted to
NADH, leading to SIRT1 deactivation. In addition, over-
nutrition and obesity reduce SIRT1 expression in various
tissues (17,19). In mammals, by controlling expression
and/or acetylation of some transcription factors and
enzymes, SIRT1 stimulates hepatic gluconeogenesis and
suppresses lipogenesis in adipocytes (17,20–22). SIRT1
is highly expressed in trophoblasts (23,24); however, its
regulatory role in placental nutrient transport has yet to be
studied.
The present study compared gene expression profiles
between placentas from HF diet– and chow-fed dams and
revealed that maternal HF feeding increases placental LPL
expression and activity accompanied by elevated peroxi-
some proliferator–activated receptor-g (PPARg) but de-
creased SIRT1 expression. Using cultured trophoblasts
and SIRT1- or PPARg-specific agonist and antagonist,
the study further demonstrated that SIRT1 suppresses
LPL expression through inhibiting PPARg. From these
results, we propose that maternal overnutrition decreases
SIRT1 expression and, consequently, increases PPARg ac-
tivity and LPL expression in the placenta.
RESEARCH DESIGN AND METHODS
Materials
Rosiglitazone (ROSI), GW9662, resveratrol (RSV), and
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
(EX-527) were from Sigma (St. Louis, MO). Anti-LPL
antibody was from GeneTex (Irvine, CA). The LPL activity
assay kit was from Cell Biolabs, Inc. (San Diego, CA).
Antibodies for PPARg, fatty acid synthase (FASN), and
b-actin proteins were from Cell Signaling Technology,
Inc. (Danvers, MA). Anti-SIRT1, CCAAT/enhancer binding
protein-a (C/EBPa), and SREBP1c antibodies were from
Santa Cruz Biotechnology (Dallas, TX). FBS, penicillin-
streptomycin, DMEM, and F-12K medium were from
Invitrogen (Carlsbad, CA). HF diet (60 kcal% from fat,
20 kcal% from protein, 20 kcal% from carbohydrate, en-
ergy density 5.24 kcal/g; catalog number D12492) was
from Research Diets, Inc. (New Brunswick, NJ). Regular
chow (17 kcal% from fat, 25 kcal% from protein, 58 kcal%
from carbohydrate, energy density 3.1 kcal/g; catalog
number 7912) was from Harlan Laboratories (Madison,
WI).
Animal Models
C57BL/6 mice were from The Jackson Laboratory (Bar
Harbor, ME). Three-month-old primiparous female mice
were used as dams. Pregnancy was determined by the
presence of a vaginal plug and was assigned the title E0.5.
HF diets were immediately provided to the vaginal plug–
positive mice. The control dams were fed regular chow.
Placentas and fetuses were collected by caesarean section
at E15.5, E17.5, and E18.5. After removing placentas and
fetuses, dam body composition was determined using
EchoMRI, which uses a specialized nuclear magnetic
resonance-magnetic resonance imaging technology with
a coefficient of variation of 3.71% (fat) or 4.55% (lean).
Experiments using mouse models were carried out under
Association for Assessment and Accreditation of Labora-
tory Animal Care guidelines with approval from the Uni-
versity of California, San Diego, Animal Care and Use
Committee.
Blood Glucose, Free FA, TG, and Insulin Assay
Blood samples were collected from dams and fetuses by
submandibular vein puncture and beheading, respectively.
Serum glucose levels were measured using glucose oxidase
reagents from Sigma. Free FA (FFA) and TG levels were
determined using kits from Wako (Richmond, VA). Serum
insulin concentrations were measured using a mouse
Diabetes 8-Plex kit and Bio-Plex MAGPIX multiplex
reader (Bio-Rad, Hercules, CA).
Placental TG and Fetal Body Fat Measurement
Placental tissues were homogenized in ice-cold PBS.
Placental lipids were extracted according to Bligh and
Dyer (25), solvents were evaporated under nitrogen bath,
and samples were redissolved in 2% Triton X (Fisher Bio-
tech, Bridgewater, NJ) in water. A kit (Wako) was used to
determine TG content. Fetal body fat was determined by
lipid extraction (26). Briefly, fetal carcasses were dried at
103°C to constant weight. The drying was followed by fat
extraction with petroleum ether (Alfa Aesar, Heysham,
U.K.) in a Soxhlet apparatus (Cole Parmer, Vernon Hills,
IL) for at least 10 cycles. Fat mass was calculated by the
difference in dry mass of the carcass before and after the
extraction.
Western Blot and Real-Time PCR Assays
Protein samples were separated using NuPAGE gels
(Invitrogen). Protein was blotted with the indicated
antibodies (see details in figure legends). The bands
from Western blots were quantified using Quantity One
software (Bio-Rad). Total RNA was prepared from pla-
centas with TRIzol (Invitrogen) following the manufac-
turer’s protocol. cDNA was synthesized using SuperScript
III Reverse Transcriptase and oligo(dT)12–18 primer (Invi-
trogen). Real-time PCR was performed using an Mx3000P
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real-time PCR system (Stratagene) and SYBR Green dye
(Molecular Probes, Eugene, OR) with an annealing tem-
perature at 60°C and gene-specific primers (Table 1). The
levels of PCR product were calculated from standard
curves established from each primer pair. Expression
data were normalized to the amount of 18S rRNA.
Cell Culture
Human BeWo and JEG-3 trophoblasts were cultured in
F-12K or DMEM with 10% FBS. Confluent cells were
transduced with adenoviral (Ad) vectors encoding SIRT1
or PPARg for 24 h. Ad-green fluorescent protein (GFP)
was used as control. The construction and purification of
the viral vectors were previously described (19).
Statistical Analysis
Data are expressed as mean 6 SEM. Statistical analyses
were performed using the Student t test or ANOVA fol-
lowed by Bonferroni posttest using Prism software. Dif-
ferences were considered significant at P , 0.05.
RESULTS
Maternal HF Feeding During Gestation Increases Fetal
Body Fat, Placental TG Content, and Fetal Serum FFA
Prepregnant maternal obesity and excessive gestational
weight gain are associated with high birth weight (1–3).
To focus on the effect of maternal overnutrition on fetal
fat accumulation and to eliminate the effects of preexist-
ing maternal obesity on fetal development, HF diets were
provided to dams only during the gestational period. Al-
though energy intake of HF-fed dams was only slightly
higher than that of controls (Supplementary Fig. 1A and
B), remarkably elevated fat tissue mass was observed in
HF-fed dams from E15.5 to E18.5 (Fig. 1A and Supple-
mentary Fig. 1C). Similar to previous rodent studies
reporting an adverse effect of maternal HF feeding on
fetal growth (27–30), we also found a trend of decreased
body weight (P = 0.0521) (Fig. 1B) and lean body mass
(Supplementary Fig. 1D) in E18.5 fetuses of HF-fed dams.
There was no change in body fat content of E18.5 fetuses
of HF-fed dams (P = 0.5437) (Fig. 1C). However, adiposity
of E18.5 fetuses from HF-fed dams was significantly
higher than that of control fetuses (Fig. 1D). At E15.5
and E17.5, no differences were seen in either fetal body
weight or adiposity (Supplementary Fig. 1E and F). To-
gether, these data indicate that gestational period HF
feeding induces both maternal and fetal adiposity in
mice. However, the effect on fetal adiposity happens in
late gestation. For the rest of the study, only E18.5 fetal
samples were analyzed.
To characterize the impact of maternal HF feeding on
fetal metabolism, we measured metabolic parameters of
blood and placentas. As shown in Fig. 1E–G, fetal serum
FFA concentration in HF-fed dams was significantly in-
creased, but TG and glucose levels were similar between
the two groups. In maternal circulation, serum glucose
and FFA levels were comparable between HF- and chow-
fed dams (Fig. 1H and I). However, there were significant
decreases in TG levels in HF-fed dams (Fig. 1J). HF feed-
ing significantly increased insulin levels in maternal blood
but not in fetal circulation (Fig. 1K and L). Apparently,
maternal HF feeding alters glucose and lipid metabolism
in both the maternal and the fetal compartment. How-
ever, the impacts on the major metabolic markers are
different between fetuses and dams. These differences
suggest that the effects of maternal obesity on fetal me-
tabolism are not simply through a passive transplacental
nutrient diffusion. Of note, a slight increase of placental
weight was found in the HF-fed group (Fig. 1M). How-
ever, placental TG levels in HF-fed dams were remarkably
higher than in the controls (Fig. 1N). The elevated fetal
serum FFA and placental TG content support the hypoth-
esis that maternal HF feeding increases placental FA
transport.
Maternal HF Feeding Increases Placental LPL
Expression and Activity
To study the effect of maternal HF feeding on placental
lipid metabolism, we compared mRNA levels of the key
Table 1—Sequences for real-time PCR primers
Gene Forward (59–39) Reverse (59–39)
18S rRNA CGAAAGCATTTGCCAAGAAT AGTCGGCATCGTTTATGGTC
LPL AATTTGCTTTCGATGTCTGAGAA CAGAGTTTGACCGCCTTCC
FASN ACTCCACAGGTGGGAACAAG CCCTTGATGAAGAGGGATCA
GPAT1 TGGGATACTGGGGTTGAAAA GGAAGGTGCTGCTATTCCTG
GPAT2 GCTGCCAGACCTGTACTCCT AGCCCAGGTCCATTATGCTT
GPAT3 GTGCTGGGTGTCCTAGTGC AAGCTGATCCCAATGAAAGC
GPAT4 CCACCCTGAGAATGGAGAGA TCCAGAGAAGTGGGATCTTTTG
SIRT1 GCTTCATGATGGCAAGTGG TCGTGGAGACATTTTTAATCAGG
VLDLr CCTATAACTAGGTCTTTGCAGATATGG GAGCCCCTGAAGGAATGCC
CD36 CCAGTGTATATGTAGGCTCATCCA TGGCCTTACTTGGGATTGG
FABP3 TGGTCATGCTAGCCACCTG CTTTGTCGGTACCTGGAAGC
FABPpm ATCTGGAGGTCCCATTTCAA ATGGCTGCTGCCTTTCAC
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genes in these processes. The results showed that mRNA
levels of genes for TG hydrolysis and FA transport, such
as LPL, CD36, VLDLr, FABP3, and FABPpm, are remarkably
increased in placentas from HF-fed dams (Fig. 2A). The
results of immunoblotting (Fig. 2B) also revealed a signifi-
cant increase in LPL and CD36 protein in placentas from
HF-fed dams. Consistent with elevated mRNA and protein
levels, significantly increased LPL activities were detected in
the placentas of HF-fed dams (Fig. 2C). Together, these
results indicate that maternal HF feeding increases expres-
sion of proteins that facilitate TG hydrolysis and FA uptake
and transport in placentas.
This study also found that expression of rate-limiting
enzymes of triacylglycerol synthesis glycerol-3-phosphate
acyltransferase 2 (GPAT2) and GPAT3 was significantly
increased by maternal HF feeding (Fig. 2A). Together with
Figure 1—Maternal HF feeding during gestation increased fetal body fat and placental TG content. Ten- to 12-week-old nulliparous
C57BL/6 female mice were mated with chow-fed males. HF diet was provided to dams once the vaginal plug was detected. Fetuses,
placentas, and other tissue samples were collected at E18.5 in the fed state through caesarean section. Increased body weight and
body fat were assayed in HF-fed dams by EchoMRI scanning (n = 6–8) (A). Fetal body fat was measured using petroleum ether fat
extraction. Although there were no remarkable differences in fetal body weight (B) and body fat (C ), significantly elevated adiposity (D)
was observed in fetuses from HF-fed dams (n = 20–36). Compared with fetuses of chow-fed dams, remarkably increased serum FFA
levels (E ) but not TG (F ) and glucose (G) levels were detected in fetuses of HF-fed dams (n = 8). Comparing HF- and chow-fed dams,
there were no significant differences in blood glucose (H) and FFA (I) levels; however, significantly decreased serum TG (J) and increased
insulin (K ) levels were found in HF-fed dams. Of note, fetal serum insulin concentrations were comparable between groups (L). There
was no difference in placental weight (M ), but placental TG content was significantly higher in the HF group (n = 6) (N ). BW, body weight;
Con, control; NS, not significant.
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increased placental TG levels (Fig. 1N), these data suggest
that maternal HF feeding increases placental FA transport
and TG synthesis, which may lead to higher placental TG
content. However, unaltered FASN expression (Fig. 2A)
implies that placental de novo lipogenesis is unlikely to
underlie maternal obesity-increased placental TGs and fetal
FFAs.
Maternal HF Feeding Increases PPARg Expression,
Leading to Stimulation of LPL Expression in
Trophoblasts
Elevated mRNA levels of LPL and other genes in placentas
from HF-fed dams suggest that the upregulation may be at
the transcriptional level. We measured protein levels of three
key lipogenic transcription factors: PPARg, C/EBPa, and
SREBP1c. Figure 3A shows that both PPARg and C/EBPa
were significantly increased in placentas of HF-fed dams,
whereas no change was apparent in mature SREBP1c.
The regulatory effects of PPARg on LPL gene expres-
sion have been reported in adipocytes (31). To verify the
role of increased PPARg in maternal HF feeding–increased
LPL expression in the placenta, we treated JEG-3 trophoblasts
with the PPARg agonist ROSI. Significantly high levels of LPL
protein and activity were found in ROSI-treated JEG-3 cells
(Fig. 3B and C), indicating that PPARg stimulates LPL expres-
sion in trophoblasts.
We next studied the effect of C/EBPa on LPL gene
expression using a C/EBPa-encoding Ad vector to trans-
duce JEG-3 cells. As shown in Fig. 3D, LPL protein levels
were similar between cells transduced with Ad-C/EBPa
and Ad-GFP. This result indicates that despite the mater-
nal HF feeding increase in C/EBPa in placentas, C/EBPa
does not increase LPL expression in trophoblasts. To-
gether, these results suggest that increased PPARg medi-
ates maternal HF feeding–enhanced LPL expression in the
placenta.
SIRT1 Inhibits LPL Gene Expression in JEG-3
Trophoblasts
SIRT1 is a protein deacetylase that plays an important
role in regulating cellular metabolism. SIRT1 expression is
enhanced by fasting or calorie restriction and inhibited by
HF feeding (22,32). As expected, significantly reduced
SIRT1 protein and mRNA levels were found in placentas
of HF-fed dams relative to controls (Fig. 4A and B), which
indicates that maternal HF feeding reduces SIRT1 expres-
sion in placentas. This observation led us to hypothesize
that decreased SIRT1 may be involved in maternal HF
feeding–altered placental lipid metabolism.
To look at the regulatory effect of SIRT1 on LPL ex-
pression, mouse embryo fibroblasts (MEFs) from Sirt12/2
and wild-type (WT) mice were used as a cellular model.
We compared LPL expression levels between WT and
Sirt12/2 MEFs. Remarkably higher levels of LPL mRNA
were detected in Sirt12/2MEFs than in WT cells (Fig. 4C),
which suggests that SIRT1 suppresses LPL expression.
To further study the effect of SIRT1 on LPL expression
in trophoblasts, we treated JEG-3 cells with the SIRT1
activator RSV or the inhibitor Ex-527. As shown in Fig.
4D, significantly reduced LPL protein levels were found in
RSV-treated cells, whereas robustly increased LPL protein
levels were observed in EX-527–treated cells. Parallel to
the changes in LPL protein expression, remarkably altered
LPL activities were detected in RSV- and EX-527–treated
Figure 1—Continued.
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JEG-3 cells (Fig. 4E). Together, these studies demonstrate
that SIRT1 inhibits LPL expression in trophoblasts.
Inhibition of PPARg Abolishes Sirt1 Knockdown–
Induced Upregulation of LPL in JEG-3 Cells
Results from the aforementioned studies demonstrate
opposite effects of PPARg and SIRT1 on LPL gene expres-
sion in trophoblasts. Of note, increased PPARg but de-
creased SIRT1 protein levels were observed in placentas
from HF-fed dams (Figs. 3A and 4A). Previous studies
demonstrated that SIRT1 inhibits PPARg expression
and activity in adipocytes (22,33,34). SIRT1 and PPARg
can reciprocally regulate each other (34,35), raising a ques-
tion about the relationship of PPARg and SIRT1 in ma-
ternal HF feeding–enhanced placental LPL expression.
Treatment of Sirt12/2 MEFs with the PPARg agonist
ROSI significantly increased LPL mRNA (Fig. 5A), indicat-
ing that PPARg upregulates LPL expression independent
of SIRT1. In addition, overnight ROSI treatment did not
change SIRT1 protein levels in JEG-3 trophoblasts (Fig.
5B). In contrast, SIRT1 activation led to a reduction in
PPARg protein levels in these cells (Fig. 4D). Together,
these results suggest that SIRT1 inhibits PPARg expres-
sion in trophoblasts. Therefore, we hypothesize that
decreased SIRT1 mediates HF feeding–induced placental
LPL expression by enhancing PPARg activity.
We used Sirt1 gene knockdown and the PPARg inhib-
itor GW9662 to test this hypothesis. Knockdown of Sirt1
significantly increased LPL gene expression (Fig. 5C); how-
ever, this stimulative effect was abolished in GW9662-treated
cells, suggesting that SIRT1 regulates LPL gene expression
through PPARg. These results also support our hypothe-
sis that maternal HF feeding increases PPARg-controlled
LPL expression by reducing SIRT1 expression in the
placenta.
DISCUSSION
Human fetal fat deposition increases exponentially with
gestational age, and most of the fat accumulation occurs
during the third trimester. Unlike humans, mice are
altricial, having a very limited amount of fat tissue at
birth. Despite the differences in fetal fat deposition, most
human and mouse studies have demonstrated a positive
association of maternal adiposity with fetal fat accumu-
lation. In the present study, all dams had similar
prepregnant body fat levels (data not shown), and the
HF diet was provided only during the gestational period.
Although total energy intake was similar, HF-fed dams
gained significantly more body fat. These data indicate
that HF feeding during gestation induces maternal
obesity in mice. The results of significantly increased
adiposity of E18.5 fetuses further demonstrate that HF
feeding or maternal obesity increases fetal fat in mice. An
interesting finding of this study is that maternal HF
feeding of mice has no significant effect on placental
weight, whereas other studies have found that maternal
BMI correlates with placental weight, which is predictive
of neonatal body weight (36,37). The discordant changes
in fetal body fat and placental mass from HF-fed dams led
us to postulate that enhanced nutrient transport activity,
rather than placental tissue mass, plays an important role
in HF feeding or maternal obesity-induced fetal fat accu-
mulation. The remarkably increased fetal blood FFA and
placental TG content from HF-fed dams support this
notion.
In the placenta, LPL is mainly expressed in syntotro-
phoblasts and catabolize TGs from maternal blood. LPL
gene expression and activity increase dramatically during
the last trimester of pregnancy, correlating with increased
placental FA transport (11,12,38). In line with two other
studies (15,39), the present study shows that maternal
HF feeding increases placental LPL activity. In addition,
expression of key genes for placental lipid transport, such
as CD36 and VLDLr, were concurrently elevated in pla-
centas of HF-fed dams. These results prompted us to pro-
pose that increased expression and activity of LPL and
other proteins enhance maternal-fetal FA transport,
which contributes to maternal overnutrition-induced fetal
fat accumulation.
Although placental LPL expression positively correlates
with fetal fat accumulation and newborn body weight, very
Figure 2—Maternal HF feeding increased placental LPL expression
and activity and genes that facilitate lipid transport. E18.5 placental
samples were collected from chow- and HF-fed dams. A: Using
real-time PCR, significantly increased mRNA of LPL and other key
genes that facilitate lipid transport were detected in placentas from
HF-fed dams (n = 6). B: Western blotting further revealed higher
protein levels of LPL and CD36 in placentas from HF-fed dams
(n = 7). C: Parallel with the increased gene expression, significantly
elevated LPL activities were found in placentas of HF-fed dams (n =
8). *P < 0.05 vs. control. Con, control.
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limited mechanistic information is available regarding how
maternal obesity and HF feeding increase LPL expression
and activity in placentas. Regulation of LPL gene expres-
sion has been extensively studied in adipose tissue,
skeletal muscle, and heart. PPARg is a nuclear receptor
known well for its key role in lipogenesis. Similar to
other types of cells (31), PPARg increases LPL expression
in trophoblasts as demonstrated in the present study.
Most importantly, the results show that maternal HF
feeding increases PPARg protein levels in placentas, sug-
gesting that increased PPARg mediates maternal HF
feeding–induced placental LPL expression. However, al-
though increased LPL activity was found in placentas of
obese mothers, no increase in PPARg mRNA or protein
levels was found in a human study (15). In addition,
increased PPARg was found only in mid-gestation placentas
of diet-induced obese ewes (40). These discrepancies
may be due to differences in species and induction of
maternal obesity.
The regulatory effects of SIRT1 on metabolism were
initially observed in aging studies of calorie-restricted
rodents. Although the beneficial effects of calorie re-
striction and SIRT1 on aging are still uncertain in
mammals, calorie restriction–induced SIRT1 expression
and activation are well conserved in many species. Pre-
vious studies have reported that prolonged calorie
Figure 3—HF feeding during pregnancy increased PPARg expression in placentas, and PPARg stimulated LPL expression in trophoblasts.
A: Significantly increased PPARg and C/EBPa protein levels were revealed in placentas of HF-fed dams (n = 7–8). *P < 0.05 vs. control.
B and C: Overnight (13 h) treatment with the PPARg agonist ROSI (10 mmol/L) robustly increased LPL expression and activities in confluent
JEG-3 trophoblasts (n = 6). D: However, Ad-C/EBPa overexpression (24 h) did not alter LPL protein levels in JEG-3 trophoblasts (n = 6).
Con, control; NS, not significant.
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restriction reduces LPL gene expression in several tissues
(41,42). In addition, significantly elevated LPL expression
was found in hepatocytes in which SIRT1 was genetically
reduced (43). These observations imply a connection be-
tween SIRT1 and LPL expression. By using an SIRT1
activator and inhibitor, the present study demonstrates
that SIRT1 inhibits LPL expression in mammalian cells,
including trophoblasts. SIRT1 is a protein deacetylase
that regulates gene expression mainly through controlling
transcription factor activity. Consistent with previous
studies (22,35,44), we found that SIRT1 reduces PPARg
in trophoblasts. Most importantly, PPARg inhibition
abolished SIRT1 knockdown–enhanced LPL expression.
These data indicate that SIRT1 regulates LPL expression
through PPARg.
During pregnancy, there is a significant adjustment of
maternal lipid metabolism. From mid-gestation to the
third trimester, maternal lipid metabolism switches from
anabolic to catabolic. Increased lipolysis provides FAs
and glycerol for maternal hepatic VLDL synthesis, which
Figure 4—Maternal HF feeding reduced expression of SIRT1, which suppresses LPL expression in trophoblasts. Western blotting and real-
time PCR demonstrated remarkably reduced SIRT1 protein (A) and mRNA (B) levels in placental samples of E18.5 HF-fed dams (n = 6).
Compared with WT MEFs, significantly higher LPL mRNA levels were found in Sirt12/2MEFs (n = 6) (C). Confluent JEG-3 trophoblasts were
treated with SIRT1 activator RSV (10 mmol/L) or inhibitor EX-527 (1 mmol/L) overnight (13 h). EX-527 treatment robustly increased LPL
protein levels and activities (D and E ). In contrast, significantly reduced LPL protein levels and activities were found in RSV-treated
trophoblasts (n = 6) (D and E). *P < 0.05 vs. control. Con, control.
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creates hypertriglyceridemia in maternal circulation (38).
Similar to humans, the present study showed that late-
pregnant mice have significantly higher blood TG concen-
trations (data not shown). To our surprise, HF feeding did
not further increase but actually reduced maternal blood
TG levels in mice (Fig. 1J). Similar to other rodent studies
(27–30), HF feeding even slightly reduced fetal body
weight in the present study. Human studies have demon-
strated that maternal blood TG levels correlate with fetal
growth (45–47). Therefore, we speculate that decreased
maternal blood TGs may underpin the decreased fetal
growth in HF-fed rodents (27–30). Another possibility
is low dietary protein supply in HF-fed mice. We found
that the daily food intake of the HF group was ;30% less
than in controls, despite similar total caloric intake (Sup-
plementary Fig. 1A and B). In addition, the HF diet con-
tained 5% less protein compared with chow. A separate
study is investigating the mechanisms through which HF
feeding reduces maternal blood TGs and fetal growth. The
intriguing observation of reduced blood TGs in HF-fed
dams raises another question about the lipid source of in-
creased placental TGs and fetal fat. The current study does
not provide data to directly answer this question. However,
similar levels of FASN and SREBP1c in placentas between
HF and control groups do not support any contribution of
de novo lipogenesis to these processes. We postulate that
despite maternal HF feeding significantly decreasing TG
levels in maternal circulation, gestation-increased blood
pool and decreased TG/FA uptake in other peripheral tis-
sues might still provide sufficient TGs for fetal supply.
Significantly elevated LPL and other genes for FA transport
in placentas of HF-fed dams increase the efficiency of pla-
cental TG hydrolysis and FA uptake.
In summary, using a pregnant mouse model, we found
that maternal HF feeding increases fetal fat accumulation.
Elevated placental LPL activity and expression of genes
that facilitate placental lipid transport suggest that en-
hanced placental lipid transport may play a key role in
maternal overnutrition and obesity-induced fetal fat accu-
mulation. Through cultured trophoblasts, the study further
demonstrates that SIRT1 inhibits LPL gene expression,
whereas maternal HF feeding reduces SIRT1 protein levels
in placentas. Inhibition of PPARg attenuates the stimula-
tive effect of SIRT1 knockdown of LPL expression. There-
fore, we propose that maternal overnutrition and obesity
reduce placental SIRT1, leading to increase PPARg trans-
activity and LPL expression in trophoblasts.
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